Tag Archives: CBAY

Analysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (NASDAQ: CBAY), Novan (NASDAQ: NOVN) and Turning Point Therapeutics (NASDAQ: TPTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CymaBay Therapeutics (CBAY – Research Report), Novan (NOVN – Research Report) and Turning Point Therapeutics (TPTX – Research Report) with bullish sentiments.

What Made B.Riley FBR Upgrade CymaBay Therapeutics’ Stock?

B.Riley FBR analyst Mayank Mamtani upgraded CymaBay Therapeutics (CBAY – Research Report) to Buy today and set a price target of $6.00. The company’s shares closed last Tuesday at $4.45. According to TipRanks.com, Mamtani is a 5-star analyst with an

B.Riley FBR Remains a Hold on CymaBay Therapeutics (CBAY)

In a report released today, Mayank Mamtani from B.Riley FBR maintained a Hold rating on CymaBay Therapeutics (CBAY – Research Report), with a price target of $1.50. The company’s shares closed last Monday at $1.35, close to its 52-week low

H.C. Wainwright Remains a Hold on CymaBay Therapeutics (CBAY)

In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on CymaBay Therapeutics (CBAY – Research Report). The company’s shares closed last Monday at $1.86, close to its 52-week low of $1.29. According to TipRanks.com, Arce

CymaBay Therapeutics (CBAY) Gets a Buy Rating from Evercore ISI

In a report issued on November 22, Joshua Schimmer from Evercore ISI maintained a Buy rating on CymaBay Therapeutics (CBAY – Research Report), with a price target of $12.00. The company’s shares closed last Monday at $5.55, close to its

Evercore ISI Reaffirms Their Buy Rating on CymaBay Therapeutics (CBAY)

Evercore ISI analyst Joshua Schimmer maintained a Buy rating on CymaBay Therapeutics (CBAY – Research Report) yesterday and set a price target of $15. The company’s shares closed last Monday at $5.95, close to its 52-week low of $4.82. According